Who are Misoprostol Pill's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Travatan, Lumigan, Xalatan, Cytotec, Caverject, Hemabate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/misoprostol-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Misoprostol Pill — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Misoprostol Pill (Misoprostol Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog. Area: Gastroenterology; Obstetrics and Gynecology.

marketed Prostaglandin analog Prostaglandin E1 receptor (EP receptor) Gastroenterology; Obstetrics and Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Misoprostol Pill (Misoprostol Pill) — University of North Carolina, Chapel Hill. Misoprostol is a prostaglandin E1 analog that binds to prostaglandin receptors to increase gastric mucus production and reduce gastric acid secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Misoprostol Pill TARGET	Misoprostol Pill	University of North Carolina, Chapel Hill	marketed	Prostaglandin analog	Prostaglandin E1 receptor (EP receptor)
Travatan	TRAVOPROST		marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	2001-01-01
Lumigan	BIMATOPROST		marketed	Prostaglandin Analog [EPC]	Aldo-keto reductase family 1 member C3	2001-01-01
Xalatan	LATANOPROST	Thea Pharma	marketed	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	1996-01-01
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Caverject	ALPROSTADIL	Pfizer	marketed	Prostaglandin Analog [EPC]	Prostaglandin E2 receptor EP3 subtype	1981-01-01
Hemabate	CARBOPROST	Pfizer	marketed	Prostaglandin Analog	Prostaglandin F2-alpha receptor	1979-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog class)

Allergan · 3 drugs in this class
AbbVie · 2 drugs in this class
Bnai Zion Medical Center · 1 drug in this class
Ibis Reproductive Health · 1 drug in this class
Ocuwize LTD · 1 drug in this class
Shaare Zedek Medical Center · 1 drug in this class
University Medical Centre Maribor · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class
University of Pennsylvania · 1 drug in this class
Wolfson Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Misoprostol Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/misoprostol-pill. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing